Guanfacine extended release - Shire

Drug Profile

Guanfacine extended release - Shire

Alternative Names: Connexyn; Intuniv; Intuniv XR; S-877503; SHP 503; SPD-503

Latest Information Update: 13 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Shire plc
  • Developer Shionogi; Shire
  • Class Acetamides; Centrally-acting antihypertensives; Chlorobenzenes; Guanidines; Phenylacetates; Small molecules
  • Mechanism of Action Alpha 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Attention-deficit hyperactivity disorder
  • No development reported Anxiety disorders; Generalised anxiety disorder; Social phobia

Most Recent Events

  • 10 Aug 2018 Preregistration for Attention-deficit hyperactivity disorder (In adults) in Japan (PO)
  • 12 Jun 2018 Shionogi completes a phase III trial in Attention-deficit hyperactivity disorder (In adults) in Japan (PO) (JapicCTI-163231)
  • 09 Jan 2018 Shionogi completes a phase II/III trial for Attention deficit hyperactivity disorder (In adolescents, In children) in Japan (JapicCTI132117)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top